CBL‑514 an kiransa da ‘allurar narkar da mai’, amma ba allura ce da ke ƙone kitse ba, ba ƙari ba, kuma ba GLP‑1 ba. Maganin ƙwaya ne da Caliway Biopharmaceuticals ke haɓaka, wanda aka tsara don haifar da apoptosis a cikin ƙwayoyin kitse a wurin da aka yi allura. A gwajin mataki na 2 da aka gudanar a 2025, ƙashin ciki ya ragu da kusan ‑216 mL a makonni 8 idan aka kwatanta da placebo, yayin da nauyin jiki bai canza ba (≈+0.02 kg). Don haka, sakamakon ya nuna rage kitse a ƙasa, ba ƙone kitse gaba ɗaya ba. Saboda yawan fita daga gwaji, ƙira ɗaya‑blind, da shiga mai tallafa, dole ne a yi nazari da hankali.
This page is available in